GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the closing of its previously announced equity financing with Samsung affiliates including Samsung C&T Corporation.

A diagnostics company behind one of the best-known rapid Covid-19 tests has put its point-of-care testing unit up for sale, aiming at a valuation of $1.5bn, as private equity buyers eye opportunities in the healthcare and life sciences sectors. 

Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Adaptive Biotechnologies said last week that its new subsidiary Digital Biotechnologies has held an initial closing of its Series A preferred stock financing and expects to raise up to $15 million in the round.

Biobeat Technologies, Ltd., developer of the first FDA-cleared, 24-hour ambulatory blood pressure monitoring (ABPM) system that is a patch-worn, cuff-less solution for diagnosis and treatment of hypertension, announced today the closing of a $50 million Series B equity financing.

German diagnostic startup Amplifold said Wednesday that it has raised €5 million ($5.8 million) in an oversubscribed seed financing round.

Circular Genomics announced Monday that it raised $15 million in a Series A financing round led by Mountain Group Partners.

International business has become a key performance driver. Mindray generated RMB 8.33 billion in overseas revenue, accounting for 49.77% of its total, up 5.39% year-on-year. Assure Tech and Alltest reported over 90% of revenue from abroad, while Cowin Biotech grew overseas revenue 40.83%.

Octave Bioscience, Inc., a commercial stage precision care company that is pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announces the close of its $35.6 million Series C equity financing and that it has entered into a $15.5 million non-dilutive term loan agreement with Silicon Valley Bank (SVB) a Division of First Citizens Bank.